ALLR

Allarity Therapeutics, Inc. NASDAQ Listed Dec 21, 2021

Healthcare ·Biotechnology ·US · allarity.com

$1.30

+0.00% vs $1.30

Mkt Cap $18.7M

52w Low $0.81 42.2% of range 52w High $1.97

50d MA $1.47 200d MA $1.28

P/E (TTM) -1.8x

EV/EBITDA —

P/B 1.9x

Debt/Equity 0.1x

ROE -114.3%

P/FCF -1.3x

RSI (14) 32.50

ATR (14) $0.12

Beta 0.01

50d MA $1.47

200d MA $1.28

Avg Volume 208.9K

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

SIC Code

2834

CIK (SEC)

1860657

Phone

401 426 4664

210 Broadway · Boston, MA 02139 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 31, 2026	AMC	-0.22	-0.19	+13.6%	1.09	+1.8%	+3.7%	+2.7%	+1.7%	-1.7%	+0.0%	—
Nov 14, 2025	AMC	-0.23	-0.19	+17.4%	1.18	+0.0%	-5.1%	+1.8%	-6.1%	-7.2%	+6.8%	—
Aug 15, 2025	AMC	-0.21	-0.15	+28.6%	0.96	-2.9%	-5.0%	-0.5%	-4.0%	+1.2%	+7.5%	—
May 9, 2025	AMC	—	-0.25	—	1.05	-3.8%	-2.9%	+2.0%	-6.7%	+4.1%	+3.0%	—
Apr 4, 2025	AMC	-8.10	-4.73	+41.6%	0.79	-9.0%	+0.6%	-5.6%	-6.6%	+3.3%	+0.8%	—
Nov 14, 2024	AMC	-8.52	-7.71	+9.5%	1.41	-0.7%	-6.4%	-8.3%	+3.3%	-4.8%	+5.9%	—
Aug 5, 2024	AMC	-0.29	-3.30	-1037.9%	4.64	+0.0%	-5.8%	-4.1%	+1.4%	+4.5%	-0.5%	—
May 14, 2024	AMC	-1.76	-664.86	-9999.0%	23.66	-7.1%	-13.8%	-1.1%	-5.0%	-1.8%	-7.7%	—
Apr 29, 2024	AMC	—	-175.51	—	41.40	-2.2%	-8.0%	+7.9%	-10.2%	-18.7%	-9.9%	—
Nov 14, 2023	AMC	-8.17	-1345.35	-9999.0%	288.00	+3.0%	+3.1%	-0.9%	+6.0%	-3.9%	+2.0%	—
Aug 14, 2023	AMC	-11.19	-15783.78	-9999.0%	1260.00	-2.4%	-7.6%	-6.7%	-5.0%	-5.8%	+8.0%	—
May 11, 2023	AMC	-7.88	—	-9999.0%	10200.00	-5.9%	-10.0%	+0.1%	-7.7%	-2.4%	-8.6%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 10	Ascendiant Capital	Maintains	Buy → Buy	—	$1.15	$1.18	+2.6%	+10.4%	-6.3%	+0.0%	+5.0%	-0.8%
Dec 9	Ascendiant Capital	Maintains	Buy → Buy	—	$1.16	$1.16	+0.0%	-1.7%	+2.6%	-1.7%	-0.9%	-7.0%
Sep 26	Ascendiant Capital	Maintains	Buy → Buy	—	$1.54	$1.52	-1.3%	+2.6%	+0.6%	-0.6%	+2.5%	+0.0%
Aug 23	Ladenburg Thalmann	Downgrade	Buy → Neutral	—	—	—	—	—	—	—	—	—
May 27	Ladenburg Thalmann	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—

Institutional (13F) — Top 7 All ↗

#	Manager	Shares	Value	Chg	Period
1	Renaissance Technologies Llc	228,084	$249K	Reduced	Mar 2026
2	Vanguard Capital Management Llc	171,795	$187K	New	Mar 2026
3	Capital Advisors Inc/ok	100,000	$108K	New	Dec 2025
4	Northern Trust Corp	48,103	$52K	Added	Mar 2026
5	Two Sigma Investments, Lp	27,492	$30K	—	Mar 2026
6	Ubs Group Ag	23,158	$25K	Reduced	Mar 2026
7	Danske Bank A/s	1	$1	—	Mar 2026

Mutual Funds / ETFs (N-PORT) — Top 3 All ↗

#	Fund	Shares	Value	Period
1	Fidelity Extended Market Index Fund	86,159	$84K	Feb 2026
2	Fidelity Total Market Index Fund	22,166	$22K	Feb 2026
3	Fidelity Series Total Market Index Fund	21,595	$21K	Feb 2026

Data updated apr 24, 2026 5:22pm · Source: financialmodelingprep.com